medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2021-18-62-67medsovet-6553Research ArticleАКТУАЛЬНОЕ В ОТОРИНОЛАРИНГОЛОГИИACTUAL IN OTORHINOLARYNGOLOGYОт клинических рекомендаций к практике. Клинический опыт лечения больных аллергическим ринитомFrom clinical guidelines to practice. Clinical experience in treatment of patients with allergic rhinitishttps://orcid.org/0000-0002-7262-1151ОвчинниковА. Ю.OvchinnikovA. Y.

Овчинников Андрей Юрьевич – доктор медицинских наук, профессор, заведующий кафедрой оториноларингологии.

127473, Москва, ул. Делегатская, д. 20, стр. 1.

Andrey Y. Ovchinnikov - Dr. Sci. (Med.), Professor, Head of the Department of Otorhinolaryngology, Yevdokimov Moscow State University of Medicine and Dentistry.

20, Bldg. 1, Delegateskaya St., Moscow, 127473.

lorent1@mail.ruhttps://orcid.org/0000-0003-4213-6435МирошниченкоН. А.MiroshnichenkoN. A.

Мирошниченко Нина Александровна - доктор медицинских наук, профессор кафедры оториноларингологии.

127473, Москва, ул. Делегатская, д. 20, стр. 1.

Nina A. Miroshnichenko - Dr. Sci. (Med.), Professor, Department of Otorhinolaryngology, Yevdokimov Moscow State University of Medicine and Dentistry.

20, Bldg. 1, Delegateskaya St., Moscow, 127473.

mirnino@yandex.ruhttps://orcid.org/0000-0002-9585-4986ХонЕ. М.KhonE. M.

Хон Елена Макаровна – кандидат медицинских наук, доцент кафедры оториноларингологии.

127473, Москва, ул. Делегатская, д. 20, стр. 1.

Elena M. Khon - Cand. Sci. (Med.), Associate Professor, Department of Otorhinolaryngology, Yevdokimov Moscow State University of Medicine and Dentistry.

20, Bldg. 1, Delegateskaya St., Moscow, 127473.

khonlena@mail.ruhttps://orcid.org/0000-0002-5502-569XДжимшелейшвилиН. П.JimsheleishviliN. P.

Джимшелейшвили Ната Паатовна - аспирант кафедры оториноларингологии.

127473, Москва, ул. Делегатская, д. 20, стр. 1.

Nata P. Jimsheleishvili - Postgraduate Student of the Department of Otorhinolaryngology, Yevdokimov Moscow State University of Medicine and Dentistry.

20, Bldg. 1, Delegateskaya St., Moscow, 127473.

npjent@gmail.comhttps://orcid.org/0000-0002-9099-711XСимсоваВ. А.SimsovаV. A.

Симсова Виктория Александровна - аспирант кафедры оториноларингологии.

127473, Москва, ул. Делегатская, д. 20, стр. 1.

Victoriya A. Simsovа - Postgraduate Student, Department of Otorhinolaryngology, Yevdokimov Moscow State University of Medicine and Dentistry.

20, Bldg. 1, Delegateskaya St., Moscow, 127473.

vika.simsova@gmail.comhttps://orcid.org/0000-0001-7930-8259НиколаеваЮ. О.NikolaevaYu. O.

Николаева Юлия Олеговна - аспирант кафедры оториноларингологии.

127473, Москва, ул. Делегатская, д. 20, стр. 1.

Yulia O. Nikolaeva - Postgraduate Student, Department of Otorhinolaryngology, Yevdokimov Moscow State University of Medicine and Dentistry.

20, Bldg. 1, Delegateskaya St., Moscow, 127473.

yu.o.nikolaeva@gmail.comМосковский государственный медико-стоматологический университет имени А.И. ЕвдокимоваРоссияYevdokimov Moscow State University of Medicine and DentistryRussian Federation2021301120210186267Copyright © Овчинников А.Ю., Мирошниченко Н.А., Хон Е.М., Джимшелейшвили Н.П., Симсова В.А., Николаева Ю.О., 20212021Овчинников А.Ю., Мирошниченко Н.А., Хон Е.М., Джимшелейшвили Н.П., Симсова В.А., Николаева Ю.О.Ovchinnikov A.Y., Miroshnichenko N.A., Khon E.M., Jimsheleishvili N.P., Simsovа V.A., Nikolaeva Y.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/6553Введение

Введение. Антигистаминные препараты являются наиболее часто назначаемым классом лекарственных средств для лечения круглогодичного аллергического ринита и сезонного аллергического ринита. Одним из таких препаратов является левоцетиризин, R-энантиомер цетиризина, являющийся избирательным антагонистом периферических гистаминовых Н1-рецепторов. В данной статье анализируются свойства левоцетиризина с точки зрения безопасности и эффективности при разных формах аллергического ринита.

Цель исследования

Цель исследования. Оценить эффективность левоцетиризина у пациентов с сезонным аллергическим ринитом (САР) и круглогодичным аллергическим ринитом (КАР) в сравнении с плацебо, а также безопасность в отношении пациентов с аллергическим ринитом.

Материалы и методы

Материалы и методы. В двойном слепом плацебо-контролируемом исследовании были рандомизированы 52 пациента с КАР и 28 пациентов с САР для получения левоцетиризина 5 мг в день однократно или плацебо. Средние общие показатели пяти симптомов (заложенность носа, зуд в носу, зуд в глазах, ринорея и чихание) сравнивались между группами лечения в течение 1, 2 и 4 нед. Также изучались все отдельные показатели симптомов.

Результаты

Результаты. Левоцетиризин показал значительное улучшение состояния пациентов с КАР и САР за весь период лечения по сравнению с плацебо. Оценка отдельных симптомов показала статистически значимые различия в пользу левоцетиризина. Выводы. Левоцетиризин продемонстрировал благоприятные характеристики, включая быстрое начало действия, высокую биодоступность, высокое сродство и активность с гистаминовыми H1-рецепторами, ограниченное распределение, минимальный метаболизм в печени вместе с минимальными неблагоприятными эффектами. Левоцетиризин является эффективным, безопасным и хорошо переносимым препаратом для лечения КАР и САР.

Introduction

Introduction. Antihistamines are the most commonly prescribed class of medications for the treatment of allergic rhinitis (AR). However, they are also widely used in the treatment of inflammatory diseases of the ENT organs. One such drug is levocytirizine, (R) an enantiomer of cetirizine, which is a selective antagonist of peripheral histamine H1-receptors. This article analyzes the properties of levocytirizine in terms of safety and efficacy in allergic rhinitis.

Aim of the study is to assess the efficacy of levocetirizine in patients with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) versus placebo, and safety for patients with allergic rhinitis.

Materials and methods

Materials and methods. In this, double-blind, placebo-controlled study, 52 patients with year-round allergic rhinitis and 28 patients with seasonal allergic rhinitis were randomized to receive levocetirizine 5 mg/day once or placebo. Mean overall measures of five symptoms (nasal congestion, nasal itching, itchy eyes, rhinorrhea, and sneezing) were compared between treatment groups at 1, 2, and 4 weeks. All individual symptom scores were also examined.

Results

Results. Levocetirizine showed a significant improvement in the condition of patients with CAR and SAR over the entire treatment period compared to placebo. Assessment of individual symptoms showed statistically significant differences in favor of levocetirizine. Conclusion. Levocetirizine is an effective, safe, and well-tolerated drug for the treatment of allergic rhinitis.

аллергияоториноларингологияаллергический ринитлевоцетиризинантигистаминные препаратыallergyotolaryngologyallergic rhinitislevocetirizineantihistaminesReferencesАстафьева Н.Г., Баранов А.А., Вишнева Е.А., Дайхес Н.А., Жестков А.В., Ильина Н.И. и др. Аллергический ринит: клинические рекомендации. М.; 2020. 84 c. Режим доступа: https://raaci.ru/dat/pdf/allergic_rhinitis.pdf.Astafyeva N.G., Baranov A.A., Vishneva Ye.A., Daykhes N.A., Zhestkov A.V., Il'ina N.I. et al. Allergic rhinitis: clinical guidelines. Moscow; 2020. 84 p. (In Russ.) Available at: https://raaci.ru/dat/pdf/allergic_rhinitis.pdf.Bousquet J., Van Cauwenberge P., Khaltaev N; Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(5 Suppl.):147-334. https://doi.org/10.1067/mai.2001.118891.Bousquet J., Van Cauwenberge P., Khaltaev N; Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(5 Suppl.):147-334. https://doi.org/10.1067/mai.2001.118891.Day J.H., Ellis A.K., Rafeiro E. Levocetirizine: a new selective H-1 receptor antagonist for use in allergic disorders. Drugs Today. 2004;40(5):415-421. https://doi.org/10.1358/dot.2004.40.5.850489.Day J.H., Ellis A.K., Rafeiro E. Levocetirizine: a new selective H-1 receptor antagonist for use in allergic disorders. Drugs Today. 2004;40(5):415-421. https://doi.org/10.1358/dot.2004.40.5.850489.Skoner D.P. Allergic rhinitis. definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001;108(1 Suppl.):2-8. https://doi.org/10.1067/mai.2001.115569.Skoner D.P. Allergic rhinitis. definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001;108(1 Suppl.):2-8. https://doi.org/10.1067/mai.2001.115569.Gillard M., Van Der Perren C., Moguilevsky N., Massingham R., Chatelain P. Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194). Mol Pharmacol. 2002;61(2):391-399. https://doi.org/10.1124/mol.61.2.391.Gillard M., Van Der Perren C., Moguilevsky N., Massingham R., Chatelain P. Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194). Mol Pharmacol. 2002;61(2):391-399. https://doi.org/10.1124/mol.61.2.391.Giustizieri M.L., Albanesi C., Fluhr J., Gisondi P., Norgauer J., Girolomoni G. H1 histamine receptor1 mediates inflammatory responses in human keratinocytes. J Allergy Clin Immunol. 2004;114(5):1176-1182. https://doi.org/10.1016/j.jaci.2004.07.054.Giustizieri M.L., Albanesi C., Fluhr J., Gisondi P., Norgauer J., Girolomoni G. H1 histamine receptor1 mediates inflammatory responses in human keratinocytes. J Allergy Clin Immunol. 2004;114(5):1176-1182. https://doi.org/10.1016/j.jaci.2004.07.054.Thomson L., Blaylock M.G., Sexton D.W., Campbell A., Walsh G.M. Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transen-dothelial migration through human dermal or lung microvascular endothelial cells. Clin Exp Allergy. 2002;32(8):1187-1192. https://doi.org/10.1046/j.1365-2745.2002.01444.x.Thomson L., Blaylock M.G., Sexton D.W., Campbell A., Walsh G.M. Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transen-dothelial migration through human dermal or lung microvascular endothelial cells. Clin Exp Allergy. 2002;32(8):1187-1192. https://doi.org/10.1046/j.1365-2745.2002.01444.x.Hulhoven R., Rosillon D., Letiexhe M., Meeus M.A., Daoust A., Stockis A. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. Eur J Clin Pharmacol. 2007;63:1011-1017. https://doi.org/10.1007/s00228-007-0366-5.Hulhoven R., Rosillon D., Letiexhe M., Meeus M.A., Daoust A., Stockis A. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. Eur J Clin Pharmacol. 2007;63:1011-1017. https://doi.org/10.1007/s00228-007-0366-5.Hasala H., Janka-Junttila M., Moilanen E., Kankaanranta H. Levocetirizine and cytokine production and apoptosis of human eosinophils. Allergy Asthma Proc. 2007;28(5):582-591. https://doi.org/10.2500/aap2007.28.3045.Hasala H., Janka-Junttila M., Moilanen E., Kankaanranta H. Levocetirizine and cytokine production and apoptosis of human eosinophils. Allergy Asthma Proc. 2007;28(5):582-591. https://doi.org/10.2500/aap2007.28.3045.Marshall G.D. Jr. Therapeutic options in allergic disease: antihistamines as systemic antiallergic agents. J Allergy Clin Immunol. 2000;106(5 Suppl.):303-309. https://doi.org/10.1067/mai.2000.110165.Marshall G.D. Jr. Therapeutic options in allergic disease: antihistamines as systemic antiallergic agents. J Allergy Clin Immunol. 2000;106(5 Suppl.):303-309. https://doi.org/10.1067/mai.2000.110165.Wang K.Y., Arima N., Higuchi S., Shimajiri S., Tanimoto A., Murata Y. et al. Switch of histamine receptor expression from H2 to H1 during differentiation of monocytes into macrophages. FEBS Lett. 2000;473(3):345-348. https://doi.org/10.1016/s0014-5793(00)01560-x.Wang K.Y., Arima N., Higuchi S., Shimajiri S., Tanimoto A., Murata Y. et al. Switch of histamine receptor expression from H2 to H1 during differentiation of monocytes into macrophages. FEBS Lett. 2000;473(3):345-348. https://doi.org/10.1016/s0014-5793(00)01560-x.Hulhoven R., Rosillon D., Letiexhe M., Meeus M.A., Daoust A., Stockis A. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. Eur J Clin Pharmacol. 2007;63:1011-1017. https://doi.org/10.1007/s00228-007-0366-5.Hulhoven R., Rosillon D., Letiexhe M., Meeus M.A., Daoust A., Stockis A. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. Eur J Clin Pharmacol. 2007;63:1011-1017. https://doi.org/10.1007/s00228-007-0366-5.Stuck B.A., Czajowski J., Hagner A.E., Klimek L., Verse T., Hormann K., Maurer J.T. Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: a controlled clinical trial. J Allergy Clin Immunol. 2004;113(4):663-668. https://doi.org/10.1016/j.jaci.2003.12.589.Stuck B.A., Czajowski J., Hagner A.E., Klimek L., Verse T., Hormann K., Maurer J.T. Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: a controlled clinical trial. J Allergy Clin Immunol. 2004;113(4):663-668. https://doi.org/10.1016/j.jaci.2003.12.589.Crystal-Peters J., Crown W.H., Goetzel R.Z., Schutt D.C. The cost of productivity losses associated with allergic rhinitis. Am J Manag Care. 2000;6(3):373-378. Available at: https://pubmed.ncbi.nlm.nih.gov/10977437.Crystal-Peters J., Crown W.H., Goetzel R.Z., Schutt D.C. The cost of productivity losses associated with allergic rhinitis. Am J Manag Care. 2000;6(3):373-378. Available at: https://pubmed.ncbi.nlm.nih.gov/10977437.Casale T.B., Blaiss M.S., Gelfand E., Gilmore T., Harvey P.D., Hindmarch I. et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol. 2003;111(5):835-842. https://doi.org/10.1067/mai.2003.1550.Casale T.B., Blaiss M.S., Gelfand E., Gilmore T., Harvey P.D., Hindmarch I. et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol. 2003;111(5):835-842. https://doi.org/10.1067/mai.2003.1550.Petecchia L., Serpero L., Silvestri M., Sabatini F., Scarso L., Rossi G.A. The histamine-induced enhanced expression of vascular cell adhesion molecule-1 by nasal polyp-derived fibroblasts is inhibited by levocetirizine. Am J Rhinol. 2006;20(5):445-449. https://doi.org/10.2500/ajr.2006.20.0796.Petecchia L., Serpero L., Silvestri M., Sabatini F., Scarso L., Rossi G.A. The histamine-induced enhanced expression of vascular cell adhesion molecule-1 by nasal polyp-derived fibroblasts is inhibited by levocetirizine. Am J Rhinol. 2006;20(5):445-449. https://doi.org/10.2500/ajr.2006.20.0796.Pasquali M., Baiardini I., Rogkakou A., Riccio A.M., Gamalero C., Descalzi D. et al. Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters. Clin Exp Allergy. 2006;36(9):1161-1167. https://doi.org/10.1111/j.1365-2222.2006.02548.x.Pasquali M., Baiardini I., Rogkakou A., Riccio A.M., Gamalero C., Descalzi D. et al. Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters. Clin Exp Allergy. 2006;36(9):1161-1167. https://doi.org/10.1111/j.1365-2222.2006.02548.x.Hasala H., Janka-Junttila M., Moilanen E., Kankaanranta H. Levocetirizine and cytokine production and apoptosis of human eosinophils. Allergy Asthma Proc. 2007;28(5):582-591. https://doi.org/10.2500/aap2007.28.3045.Hasala H., Janka-Junttila M., Moilanen E., Kankaanranta H. Levocetirizine and cytokine production and apoptosis of human eosinophils. Allergy Asthma Proc. 2007;28(5):582-591. https://doi.org/10.2500/aap2007.28.3045.Lee D.K., Gray R.D., Wilson A.M., Robb F.M., Soutar P.C., Lipworth B.J. Single and short term dosing effects of levocetirizine in adenosine monophosphate brochoprovocation in atopic asthma. Br J Clin Pharmacol. 2004;58(1):34-39. https://doi.org/10.1111/j.1365-2125.2004.02110.x.Lee D.K., Gray R.D., Wilson A.M., Robb F.M., Soutar P.C., Lipworth B.J. Single and short term dosing effects of levocetirizine in adenosine monophosphate brochoprovocation in atopic asthma. Br J Clin Pharmacol. 2004;58(1):34-39. https://doi.org/10.1111/j.1365-2125.2004.02110.x.Hide M., Francis D.M., Grattan C.E., Hakimi J., Kochan J.P., Greaves M.W. Autoantibodies against the high affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993;328:1599-1604. https://doi.org/10.1056/NEJM199306033282204.Hide M., Francis D.M., Grattan C.E., Hakimi J., Kochan J.P., Greaves M.W. Autoantibodies against the high affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993;328:1599-1604. https://doi.org/10.1056/NEJM199306033282204.Frossard N., Strolin-Benedetti M., Purohit A, Pauli G. Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine. Br J Clin Pharmacol. 2008;65(2):172-179. https://doi.org/10.1111/j.1365-2125.2007.03009.x.Frossard N., Strolin-Benedetti M., Purohit A, Pauli G. Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine. Br J Clin Pharmacol. 2008;65(2):172-179. https://doi.org/10.1111/j.1365-2125.2007.03009.x.Mahmoud F., Arifhodzic N., Haines D., Novotney L. Levocetirizine modulates lymphocyte activation in patients with allergic rhinitis. J Pharmacol Sci. 2008;108(2):149-156. https://doi.org/10.1254/jphs.08037fp.Mahmoud F., Arifhodzic N., Haines D., Novotney L. Levocetirizine modulates lymphocyte activation in patients with allergic rhinitis. J Pharmacol Sci. 2008;108(2):149-156. https://doi.org/10.1254/jphs.08037fp.Zhang L., Cheng L., Hong J. The clinical use of cetirizine in the treatment of allergic rhinitis. Pharmacology. 2013;92(1-2):14-25. https://doi.org/10.1159/000351843.Zhang L., Cheng L., Hong J. The clinical use of cetirizine in the treatment of allergic rhinitis. Pharmacology. 2013;92(1-2):14-25. https://doi.org/10.1159/000351843.Verster J.C., de Weert A.M., Bijtjes S.I.R., Aarab M., van Oosterwijck A.A., Eijken E.J.E. et al. Driving ability after acute and subchronic administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebocontrolled trial. Psychopharmacology. 2003;169:84-90. https://doi.org/10.1007/s00213-003-1462-6.Verster J.C., de Weert A.M., Bijtjes S.I.R., Aarab M., van Oosterwijck A.A., Eijken E.J.E. et al. Driving ability after acute and subchronic administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebocontrolled trial. Psychopharmacology. 2003;169:84-90. https://doi.org/10.1007/s00213-003-1462-6.Hiraoka K., Tashiro M., Grobosch T., Maurer M., Oda K., Toyohara J. et al. Brain histamine H1 receptor occupancy measured by PET after oral administration of levocetirizine, a non-sedating antihistamine. Expert Opin Drug Saf. 2015;14(2):199-206. https://doi.org/10.1517/14740338.2015.989831.Hiraoka K., Tashiro M., Grobosch T., Maurer M., Oda K., Toyohara J. et al. Brain histamine H1 receptor occupancy measured by PET after oral administration of levocetirizine, a non-sedating antihistamine. Expert Opin Drug Saf. 2015;14(2):199-206. https://doi.org/10.1517/14740338.2015.989831.Gandon J.M., Allain H. Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers. Br J Clin Pharmacol. 2002;54(1):51-58. https://doi.org/10.1046/j.1365-2125.2002.01611.x.Gandon J.M., Allain H. Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers. Br J Clin Pharmacol. 2002;54(1):51-58. https://doi.org/10.1046/j.1365-2125.2002.01611.x.Grant J.A., Riethuisen J.M., Moulaert B., DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol. 2002;88(2):190-197. https://doi.org/10.1016/S1081-1206(10)61995-3.Grant J.A., Riethuisen J.M., Moulaert B., DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol. 2002;88(2):190-197. https://doi.org/10.1016/S1081-1206(10)61995-3.Stubner P., Zieglmayer R., Horak F. A direct comparison of the efficacy of antihistamines in SAR and PAR. randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit - the Vienna Challenge Chamber (VCC). Curr Med Res Opinion. 2004;20(6):891-902. https://doi.org/10.1185/030079904125003700.Stubner P., Zieglmayer R., Horak F. A direct comparison of the efficacy of antihistamines in SAR and PAR. randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit - the Vienna Challenge Chamber (VCC). Curr Med Res Opinion. 2004;20(6):891-902. https://doi.org/10.1185/030079904125003700.Passalacqua G., Guerra L., Compalati E., Massacane P., Rogkakou A., Zanella C. et al. Comparison of the effects in the nose and skin of a single dose of desloratadine and levocetirizine over 24 hours. Int Arch Allergy Clin Immunol. 2004;135:143-147. https://doi.org/10.1159/000080657.Passalacqua G., Guerra L., Compalati E., Massacane P., Rogkakou A., Zanella C. et al. Comparison of the effects in the nose and skin of a single dose of desloratadine and levocetirizine over 24 hours. Int Arch Allergy Clin Immunol. 2004;135:143-147. https://doi.org/10.1159/000080657.Ciprandi G., Cirillo I., Vizzaccaro A., Tosca M.A. Levocetirizine improves nasal obstruction and modulates cytocine pattern in patients with seasonal allergic rhinitis: a pilot study. Clin Exp Allergy. 2004;34(6):958-964. https://doi.org/10.1111/j.1365-2222.2004.01960.x.Ciprandi G., Cirillo I., Vizzaccaro A., Tosca M.A. Levocetirizine improves nasal obstruction and modulates cytocine pattern in patients with seasonal allergic rhinitis: a pilot study. Clin Exp Allergy. 2004;34(6):958-964. https://doi.org/10.1111/j.1365-2222.2004.01960.x.Potter P.C. Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult sensitized to house dust mites. Allergy. 2003;58(9):893-899. https://doi.org/10.1034/j.1398-9995.2003.00171.x.Potter P.C. Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult sensitized to house dust mites. Allergy. 2003;58(9):893-899. https://doi.org/10.1034/j.1398-9995.2003.00171.x.Bousquet J., Demarteau N., Mullol J., van den Akker-van Marle M.E., Van Ganse E., Bachert C. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy. 2005;60(6):788-794. https://doi.org/10.1111/j.1398-9995.2005.00820.x.Bousquet J., Demarteau N., Mullol J., van den Akker-van Marle M.E., Van Ganse E., Bachert C. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy. 2005;60(6):788-794. https://doi.org/10.1111/j.1398-9995.2005.00820.x.

The authors declare that there are no conflicts of interest present.